ZNTL News and Press, Zentalis Pharmaceuticals Inc. From 06/02/23

2023-06-02 14:34:00 ET Shares of Zentalis Pharmaceuticals (NASDAQ: ZNTL) were down 13.5% for the week as of Friday afternoon, according to data provided by S&P Global Market Intelligence . The healthcare company closed last week at $30.05 then fell as low as $25.17 on Th...

2023-05-30 14:55:16 ET After closing up ~10.6% on Friday following the release of phase 1 data on ovarian cancer candidate azenosertib, Zentalis Pharmaceuticals ( NASDAQ: ZNTL ) has given back those gains. As of 250p ET, the stock is down 11% . Data released late o...

2023-05-25 18:08:05 ET Gainers: Elevation Oncology ( ELEV ) +45% . Marvell Technology ( MRVL ) +18% . Workday ( WDAY ) +8% . Veritone ( VERI ) +6% . Paramount Global ( PARA ) +6% . Losers: Nano Labs  ( NA ) -12...

Strong anti-tumor activity shown in a platinum-resistant ovarian cancer population, with a confirmed ORR of 50.0% and mPFS of 7.4 months in combination with paclitaxel, and a confirmed ORR of 35.7% and mPFS of 10.4 months in combination with carboplatin Patients with Cyclin E1+ tumors b...

Overview of data to be presented at the 2023 ASCO Annual Meeting to be included in the update Live webcast to be held on Tuesday, June 6 th at 8:00 a.m. ET NEW YORK and SAN DIEGO, May 23, 2023 (GLOBE NEWSWIRE) -- Zentalis ® Pharmaceuticals, Inc. (Nasdaq: ZNTL)...

2023-05-19 15:00:19 ET Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week, or the Seeking Alpha earnings calendar ...

2023-05-18 10:59:22 ET S3 Partners dug into the short interest data on U.S. stocks to find the names that are seeing the most pressure exerted on investors with short positions. Ihor Dusaniwsky filtered the stock universe to pull out squeeze candidates with over $50M worth of short inte...

2023-05-10 13:28:03 ET Zentalis Pharmaceuticals press release ( NASDAQ: ZNTL ): Q1 GAAP EPS of -$1.07. $392 million cash balance as of March 31, 2023, with projected cash runway into the second quarter of 2025 Cash and Marketable Securities Position: As of ...

On track to disclose monotherapy dose and updates on currently accruing trials for azenosertib, a potentially first-in-class and best-in-class WEE1 inhibitor, in 1H 2023 Positive Phase 1b azenosertib + chemotherapy clinical data in ovarian cancer to be presented ahead of original guidan...

Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with azenosertib Company also announces collaborations with Foundation Medicine and R...